Search

Your search keyword '"Scolyer, Richard A."' showing total 3,119 results
Start Over Author "Scolyer, Richard A."
3,119 results on '"Scolyer, Richard A."'

2. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

Author

Zijlker, Lisanne P., Chen, Henry, Spillane, Andrew J., Gonzalez, Maria, Pennington, Thomas E., Menzies, Alexander M., Lo, Serigne N., Ferguson, Peter, Rawson, Robert, Colebatch, Andrew J., Stretch, Jonathan R., Thompson, John F., Ch’ng, Sydney, Nieweg, Omgo, Shannon, Kerwin F., Long, Georgina V., Scolyer, Richard A., Saw, Robyn P. M., and van Akkooi, Alexander C. J.

Published
2024
Full Text
View/download PDF

3. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

Author

Zijlker, Lisanne P., Chen, Henry, Spillane, Andrew J., Gonzalez, Maria, Pennington, Thomas E., Menzies, Alexander M., Lo, Serigne N., Ferguson, Peter, Rawson, Robert, Colebatch, Andrew J., Stretch, Jonathan R., Thompson, John F., Ch’ng, Sydney, Nieweg, Omgo, Shannon, Kerwin F., Long, Georgina V., Scolyer, Richard A., Saw, Robyn P. M., and van Akkooi, Alexander C. J.

Published
2024
Full Text
View/download PDF

6. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

Author

Gjorup, Caroline A., Woodford, Rachel, Li, Isabel, Carlino, Matteo S., Ch’ng, Sydney, Chung, David, Hsiao, Edward, Lo, Serigne N., London, Kevin, Long, Georgina V., Menzies, Alexander M., Nieweg, Omgo E., Pennington, Thomas E., Rtshiladze, Michael A., Saw, Robyn P. M., Scolyer, Richard A., Shannon, Kerwin F., Spillane, Andrew J., Stretch, Jonathan R., Thompson, John F., Varey, Alexander H. R., and van Akkooi, Alexander C. J.

Published
2024
Full Text
View/download PDF

8. Interobserver agreement in the histopathological classification of desmoplastic melanomas.

Author

Lezcano, Cecilia, Berwick, Marianne, Luo, Li, Barnhill, Raymond, Duncan, Lyn, Gerami, Pedram, Lowe, Lori, Messina, Jane, Scolyer, Richard, Wood, Benjamin, Yeh, Iwei, Zembowicz, Artur, and Busam, Klaus

Subjects
Desmoplastic, angiotropism, melanoma, mixed, neurotropism, pure, Humans, Skin Neoplasms, Observer Variation, Melanoma, Prognosis
Abstract

Desmoplastic melanoma is a subtype of melanoma characterised by amelanotic fusiform melanocytes dispersed in a collagenous stroma. Cell-poor and fibrous stroma-rich pure variants have been distinguished from mixed variants with areas of higher cell density and/or less desmoplastic stroma. This distinction is relevant because patients whose tumours display a pure phenotype have a lower risk for regional lymph node metastasis and distant recurrence. However, little is known about interobserver agreement among pathologists in the subclassification of desmoplastic melanoma. To address this issue, we conducted a study in which eleven dermatopathologists independently evaluated whole slide scanned images of excisions from 30 desmoplastic melanomas. The participating pathologists were asked to classify the tumours as pure or mixed. They were also asked to record the presence or absence of neurotropism and angiotropism. We found substantial interobserver agreement between the 11 dermatopathologists in the classification of tumours as pure versus mixed desmoplastic melanoma (kappa=0.64; p

Published
2023

9. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.

Author

Wilmott, James, Tawbi, Hussein, Engh, Johnathan, Amankulor, Nduka, Shivalingam, Brindha, Banerjee, Hiya, Vergara, Ismael, Lee, Hansol, Johansson, Peter, Ferguson, Peter, Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Scolyer, Richard, Kirkwood, John, Long, Georgina, Davies, Michael, and Butterfield, Lisa

Subjects
Humans, Proto-Oncogene Proteins B-raf, Melanoma, Oximes, Pyridones, Brain Neoplasms, Biomarkers, Antineoplastic Combined Chemotherapy Protocols, Mutation, Skin Neoplasms
Abstract

PURPOSE: This study aimed to identify baseline clinical features associated with the outcomes of patients enrolled in the COMBI-MB phase II study of dabrafenib and trametinib treatment in patients with V600 BRAF-mutant metastatic melanoma with melanoma brain metastases (MBM). Exploratory biomarker analysis was also conducted as part of the synergistic COMBI-BRV trial (BRV116521), to identify molecular and immunologic changes associated with dabrafenib in MBMs and extracranial metastases (ECM). PATIENTS AND METHODS: Post hoc analysis was performed for baseline features of patients (n = 125) enrolled in COMBI-MB. Analyses were performed to identify baseline clinical features associated with intracranial response rate (ICRR), progression-free survival (PFS), and overall survival (OS). UNLABELLED: Exploratory biomarker analysis was performed on biospecimen collected in the COMBI-BRV trial in which patients with BRAF-mutant, resectable MBM were treated with dabrafenib for 10 to 14 days prior to craniotomy. Accessible ECM were resected or biopsied at the time of craniotomy. Biospecimens underwent molecular and immunologic profiling for comparative analyses. RESULTS: In COMBI-MB baseline treatment with corticosteroids was independently associated with lower ICRR [39% vs. 63%; OR, 0.323; 95 % confidence interval (CI), 0.105-0.996; P = 0.049] and shorter PFS (HR, 1.93; 95% CI, 1.06-3.51; P = 0.031). Additional significant associations identified in the multivariate analysis were improved PFS in patients with a BRAFV600E genotype (HR, 0.565; 95% CI, 0.321-0.996; P = 0.048) and improved OS in patients with Eastern Cooperative Oncology Group 0 (HR, 0.44; 95% CI, 0.25-0.78; P = 0.005). CONCLUSIONS: Corticosteroid treatment was associated with reduced ICRR and PFS in COMBI-MB, similar to results with immunotherapy for MBMs. Baseline corticosteroid treatment is a key factor to consider in MBM patient management and clinical trial design/interpretation.

Published
2023

10. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions

Author

Barnhill, Raymond L, Elder, David E, Piepkorn, Michael W, Knezevich, Stevan R, Reisch, Lisa M, Eguchi, Megan M, Bastian, Boris C, Blokx, Willeke, Bosenberg, Marcus, Busam, Klaus J, Carr, Richard, Cochran, Alistair, Cook, Martin G, Duncan, Lyn M, Elenitsas, Rosalie, de la Fouchardière, Arnaud, Gerami, Pedram, Johansson, Iva, Ko, Jennifer, Landman, Gilles, Lazar, Alexander J, Lowe, Lori, Massi, Daniela, Messina, Jane, Mihic-Probst, Daniela, Parker, Douglas C, Schmidt, Birgitta, Shea, Christopher R, Scolyer, Richard A, Tetzlaff, Michael, Xu, Xiaowei, Yeh, Iwei, Zembowicz, Artur, and Elmore, Joann G

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Clinical Research, Cancer, Humans, Skin Neoplasms, Melanoma, Pathologists, Consensus, Health Facilities, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceA standardized pathology classification system for melanocytic lesions is needed to aid both pathologists and clinicians in cataloging currently existing diverse terminologies and in the diagnosis and treatment of patients. The Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) has been developed for this purpose.ObjectiveTo revise the MPATH-Dx version 1.0 classification tool, using feedback from dermatopathologists participating in the National Institutes of Health-funded Reducing Errors in Melanocytic Interpretations (REMI) Study and from members of the International Melanoma Pathology Study Group (IMPSG).Evidence reviewPracticing dermatopathologists recruited from 40 US states participated in the 2-year REMI study and provided feedback on the MPATH-Dx version 1.0 tool. Independently, member dermatopathologists participating in an IMPSG workshop dedicated to the MPATH-Dx schema provided additional input for refining the MPATH-Dx tool. A reference panel of 3 dermatopathologists, the original authors of the MPATH-Dx version 1.0 tool, integrated all feedback into an updated and refined MPATH-Dx version 2.0.FindingsThe new MPATH-Dx version 2.0 schema simplifies the original 5-class hierarchy into 4 classes to improve diagnostic concordance and to provide more explicit guidance in the treatment of patients. This new version also has clearly defined histopathological criteria for classification of classes I and II lesions; has specific provisions for the most frequently encountered low-cumulative sun damage pathway of melanoma progression, as well as other, less common World Health Organization pathways to melanoma; provides guidance for classifying intermediate class II tumors vs melanoma; and recognizes a subset of pT1a melanomas with very low risk and possible eventual reclassification as neoplasms lacking criteria for melanoma.Conclusions and relevanceThe implementation of the newly revised MPATH-Dx version 2.0 schema into clinical practice is anticipated to provide a robust tool and adjunct for standardized diagnostic reporting of melanocytic lesions and management of patients to the benefit of both health care practitioners and patients.

Published
2023

12. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms

Author

Chen, Alice, Sharma, Natasha, Patel, Pragi, Olivares, Shantel, Bahrami, Armita, Barnhill, Raymond L., Blokx, Willeke A.M., Bosenberg, Marcus, Busam, Klaus J., de La Fouchardière, Arnaud, Duncan, Lyn M., Elder, David E., Ko, Jennifer S., Landman, Gilles, Lazar, Alexander J., Lezcano, Cecilia, Lowe, Lori, Maher, Nigel, Massi, Daniela, Messina, Jane, Mihic-Probst, Daniela, Parker, Douglas C., Redpath, Margaret, Scolyer, Richard A., Shea, Christopher R., Spatz, Alan, Tron, Victor, Xu, Xiaowei, Yeh, Iwei, Jung Yun, Sook, Zembowicz, Artur, and Gerami, Pedram

Published
2024
Full Text
View/download PDF

13. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms

Author

Gerami, Pedram, Chen, Alice, Sharma, Natasha, Patel, Pragi, Hagstrom, Michael, Kancherla, Pranav, Geraminejad, Tara, Olivares, Shantel, Biswas, Asok, Bosenberg, Marcus, Busam, Klaus J., de La Fouchardière, Arnaud, Duncan, Lyn M., Elder, David E., Ko, Jennifer, Landman, Gilles, Lazar, Alexander J., Lowe, Lori, Massi, Daniela, Mihic-Probst, Daniela, Parker, Douglas C., Scolyer, Richard A., Shea, Christopher R., Zembowicz, Artur, Yun, Sook Jung, Blokx, Willeke A.M., and Barnhill, Raymond L.

Published
2024
Full Text
View/download PDF

14. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

Author

Gjorup, Caroline A., Woodford, Rachel, Li, Isabel, Carlino, Matteo S., Ch’ng, Sydney, Chung, David, Hsiao, Edward, Lo, Serigne N., London, Kevin, Long, Georgina V., Menzies, Alexander M., Nieweg, Omgo E., Pennington, Thomas E., Rtshiladze, Michael A., Saw, Robyn P. M., Scolyer, Richard A., Shannon, Kerwin F., Spillane, Andrew J., Stretch, Jonathan R., Thompson, John F., Varey, Alexander H. R., and van Akkooi, Alexander C. J.

Published
2024
Full Text
View/download PDF

15. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis

Author

Stassen, Robert C, Maas, Carolien C H M, van der Veldt, Astrid A M, Lo, Serigne N, Saw, Robyn P M, Varey, Alexander H R, Scolyer, Richard A, Long, Georgina V, Thompson, John F, Rutkowski, Piotr, Keilholz, Ulrich, van Akkooi, Alexander C J, Verhoef, Cornelis, van Klaveren, David, and Grünhagen, Dirk J

Published
2024
Full Text
View/download PDF

16. Uncovering the complex relationship between balding, testosterone and skin cancers in men

Author

Ong, Jue-Sheng, Seviiri, Mathias, Dusingize, Jean Claude, Wu, Yeda, Han, Xikun, Shi, Jianxin, Olsen, Catherine M., Neale, Rachel E., Thompson, John F., Saw, Robyn P. M., Shannon, Kerwin F., Mann, Graham J., Martin, Nicholas G., Medland, Sarah E., Gordon, Scott D., Scolyer, Richard A., Long, Georgina V., Iles, Mark M., Landi, Maria Teresa, Whiteman, David C., MacGregor, Stuart, and Law, Matthew H.

Published
2023
Full Text
View/download PDF

17. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

Author

Mao, Yizhe, Gide, Tuba N., Adegoke, Nurudeen A., Quek, Camelia, Maher, Nigel, Potter, Alison, Patrick, Ellis, Saw, Robyn P. M., Thompson, John F., Spillane, Andrew J., Shannon, Kerwin F., Carlino, Matteo S., Lo, Serigne N., Menzies, Alexander M., da Silva, Inês Pires, Long, Georgina V., Scolyer, Richard A., and Wilmott, James S.

Published
2023
Full Text
View/download PDF

22. Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial

Author

Menzies, Scott W, Sinz, Christoph, Menzies, Michelle, Lo, Serigne N, Yolland, William, Lingohr, Johann, Razmara, Majid, Tschandl, Philipp, Guitera, Pascale, Scolyer, Richard A, Boltz, Florentina, Borik-Heil, Liliane, Herbert Chan, Hsien, Chromy, David, Coker, David J, Collgros, Helena, Eghtedari, Maryam, Corral Forteza, Marina, Forward, Emily, Gallo, Bruna, Geisler, Stephanie, Gibson, Matthew, Hampel, Amelie, Ho, Genevieve, Junez, Laura, Kienzl, Philipp, Martin, Arthur, Moloney, Fergal J, Regio Pereira, Amanda, Ressler, Julia Maria, Richter, Susanne, Silic, Katharina, Silly, Thomas, Skoll, Michael, Tittes, Julia, Weber, Philipp, Weninger, Wolfgang, Weiss, Doris, Woo-Sampson, Ping, Zilberg, Catherine, and Kittler, Harald

Published
2023
Full Text
View/download PDF

23. Looking beyond workforce parity: addressing gender inequity in pathology

Author

McKenzie, Catriona A., Gupta, Ruta, Jackett, Louise, Anderson, Lyndal, Chen, Vivien, Dahlstrom, Jane E., Dray, Michael, Farshid, Gelareh, Hemmings, Chris, Karim, Rooshdiya, Kench, James G., Klebe, Sonja, Kramer, Nicole, Kumarasinghe, Priyanthi, Maclean, Fiona, Morey, Adrienne, Nguyen, Minh Anh, O'Toole, Sandra, Rowbotham, Beverley, Salisbury, Elizabeth L.C., Scolyer, Richard A., Stewart, Katie, Waring, Lynette, Cooper, Caroline L., and Cooper, Wendy A.

Published
2023
Full Text
View/download PDF

25. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Author

Garbe, Claus, Dummer, Reinhard, Amaral, Teresa, Amaria, Rodabe N., Ascierto, Paolo A., Burton, Elizabeth M., Dreno, Brigitte, Eggermont, Alexander M. M., Hauschild, Axel, Hoeller, Christoph, Kaufmann, Roland, Lebbe, Celeste, Mandala, Mario, Menzies, Alexander M., Moreno, David, Michielin, Olivier, Nathan, Paul, Patel, Sapna P., Robert, Caroline, Schadendorf, Dirk, Lorigan, Paul C., Scolyer, Richard A., Tawbi, Hussein A., van de Wiel, Bart A., Blank, Christian, and Long, Georgina V.

Published
2023
Full Text
View/download PDF

26. Cutaneous melanoma

Author

Long, Georgina V, Swetter, Susan M, Menzies, Alexander M, Gershenwald, Jeffrey E, and Scolyer, Richard A

Published
2023
Full Text
View/download PDF

30. L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases

Author

Barnhill, Raymond, van Laere, Steven, Vermeulen, Peter, Roman-Roman, Sergio, Gardrat, Sophie, Alsafadi, Samar, Tarin, Malcy, Champenois, Gabriel, Nicolas, André, Matet, Alexandre, Cassoux, Nathalie, Servois, Vincent, Rodrigues, Manuel, Scolyer, Richard, Lazar, Alexander, Romano, Emanuela, Piperno-Neumann, Sophie, Mariani, Pascale, and Lugassy, Claire

Published
2022
Full Text
View/download PDF

31. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Author

Simpson, Rebecca C., Shanahan, Erin R., Batten, Marcel, Reijers, Irene L. M., Read, Mark, Silva, Ines P., Versluis, Judith M., Ribeiro, Rosilene, Angelatos, Alexandra S., Tan, Jian, Adhikari, Chandra, Menzies, Alexander M., Saw, Robyn P. M., Gonzalez, Maria, Shannon, Kerwin F., Spillane, Andrew J., Velickovic, Rebecca, Lazar, Alexander J., Damania, Ashish V., Mishra, Aditya K., Chelvanambi, Manoj, Banerjee, Anik, Ajami, Nadim J., Wargo, Jennifer A., Macia, Laurence, Holmes, Andrew J., Wilmott, James S., Blank, Christian U., Scolyer, Richard A., and Long, Georgina V.

Published
2022
Full Text
View/download PDF

33. Prognostic Gene Expression Profiling in Cutaneous Melanoma

Author

Grossman, Douglas, Okwundu, Nwanneka, Bartlett, Edmund K, Marchetti, Michael A, Othus, Megan, Coit, Daniel G, Hartman, Rebecca I, Leachman, Sancy A, Berry, Elizabeth G, Korde, Larissa, Lee, Sandra J, Bar-Eli, Menashe, Berwick, Marianne, Bowles, Tawnya, Buchbinder, Elizabeth I, Burton, Elizabeth M, Chu, Emily Y, Curiel-Lewandrowski, Clara, Curtis, Julia A, Daud, Adil, Deacon, Dekker C, Ferris, Laura K, Gershenwald, Jeffrey E, Grossmann, Kenneth F, Hu-Lieskovan, Siwen, Hyngstrom, John, Jeter, Joanne M, Judson-Torres, Robert L, Kendra, Kari L, Kim, Caroline C, Kirkwood, John M, Lawson, David H, Leming, Philip D, Long, Georgina V, Marghoob, Ashfaq A, Mehnert, Janice M, Ming, Michael E, Nelson, Kelly C, Polsky, David, Scolyer, Richard A, Smith, Eric A, Sondak, Vernon K, Stark, Mitchell S, Stein, Jennifer A, Thompson, John A, Thompson, John F, Venna, Suraj S, Wei, Maria L, and Swetter, Susan M

Subjects
Cancer, Clinical Research, Patient Safety, Prevention, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Clinical Decision-Making, Consensus, Consensus Development Conferences as Topic, Gene Expression Profiling, Humans, Melanoma, Neoplasm Staging, Practice Guidelines as Topic, Prognosis, Sentinel Lymph Node Biopsy, Skin Neoplasms, Clinical Sciences, Oncology and Carcinogenesis
Abstract

ImportanceUse of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care.ObjectiveTo develop guidelines within the national Melanoma Prevention Working Group (MPWG) on integration of GEP testing into the management of patients with CM, including (1) review of published data using GEP tests, (2) definition of acceptable performance criteria, (3) current recommendations for use of GEP testing in clinical practice, and (4) considerations for future studies.Evidence reviewThe MPWG members and other international melanoma specialists participated in 2 online surveys and then convened a summit meeting. Published data and meeting abstracts from 2015 to 2019 were reviewed.FindingsThe MPWG members are optimistic about the future use of prognostic GEP testing to improve risk stratification and enhance clinical decision-making but acknowledge that current utility is limited by test performance in patients with stage I disease. Published studies of GEP testing have not evaluated results in the context of all relevant clinicopathologic factors or as predictors of regional nodal metastasis to replace sentinel lymph node biopsy (SLNB). The performance of GEP tests has generally been reported for small groups of patients representing particular tumor stages or in aggregate form, such that stage-specific performance cannot be ascertained, and without survival outcomes compared with data from the American Joint Committee on Cancer 8th edition melanoma staging system international database. There are significant challenges to performing clinical trials incorporating GEP testing with SLNB and adjuvant therapy. The MPWG members favor conducting retrospective studies that evaluate multiple GEP testing platforms on fully annotated archived samples before embarking on costly prospective studies and recommend avoiding routine use of GEP testing to direct patient management until prospective studies support their clinical utility.Conclusions and relevanceMore evidence is needed to support using GEP testing to inform recommendations regarding SLNB, intensity of follow-up or imaging surveillance, and postoperative adjuvant therapy. The MPWG recommends further research to assess the validity and clinical applicability of existing and emerging GEP tests. Decisions on performing GEP testing and patient management based on these results should only be made in the context of discussion of testing limitations with the patient or within a multidisciplinary group.

Published
2020

35. Hypoxia Controls the Glycome Signature and Galectin-8–Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma

Author

Chakraborty, Asmi, Perez, Mariana, Carroll, Jordan D., Antonopoulos, Aristotelis, Dell, Anne, Ortega, Liettel, Mohammed, Norhan B.B., Wells, Michael, Staudinger, Caleb, Griswold, Anthony, Chandler, Kevin B., Marrero, Cristina, Jimenez, Ramon, Tani, Yoshihiko, Wilmott, James S., Thompson, John F., Wang, Wei, Sackstein, Robert, Scolyer, Richard A., Murphy, George F., Haslam, Stuart M., and Dimitroff, Charles J.

Published
2023
Full Text
View/download PDF

37. Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study

Author

Moncrieff, Marc D., Lo, Serigne N., Scolyer, Richard A., Heaton, Martin J., Nobes, Jenny P., Snelling, Andrew P., Carr, Michael J., Nessim, Carolyn, Wade, Ryckie, Peach, A. Howard, Kisyova, Rumi, Mason, Jennifer, Wilson, Ewan D., Nolan, Grant, Pritchard Jones, Rowan, Sondak, Vernon K., Thompson, John F., and Zager, Jonathan S.

Published
2022
Full Text
View/download PDF

38. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Author

Blank, Christian U., primary, Lucas, Minke W., additional, Scolyer, Richard A, additional, van de Wiel, Bart A., additional, Menzies, Alexander M., additional, Lopez-Yurda, Marta I., additional, van Akkooi, Alexander Christopher Jonathan, additional, van Houdt, Winan J., additional, Saw, Robyn P.M., additional, Torres Acosta, Alex, additional, Lo, Serigne N, additional, Hospers, Geke, additional, Carlino, Matteo S., additional, de Groot, Jan Willem, additional, Kapiteijn, Ellen, additional, Suijkerbuijk, Karijn, additional, Rutkowski, Piotr, additional, Sandhu, Shahneen, additional, Van Der Veldt, Astrid Aplonia Maria, additional, and Long, Georgina V., additional

Published
2024
Full Text
View/download PDF

39. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

Author

Gonzalez, Maria, primary, van Akkooi, Alexander Christopher Jonathan, additional, Ch'ng, Sydney, additional, Shannon, Kerwin Frank, additional, Spillane, Andrew John, additional, Stretch, Jonathan, additional, Rtshiladze, Michael Alexander, additional, Pennington, Thomas, additional, Coker, David, additional, Saw, Robyn P.M., additional, Kapoor, Rony, additional, Hsiao, Edward, additional, Rawson, Robert V, additional, Osorio, Monica, additional, Menzies, Alexander M., additional, Lo, Serigne N, additional, Scolyer, Richard A, additional, Hong, Angela M, additional, Long, Georgina V., additional, and Pires Da Silva, Ines Esteves Domingues, additional

Published
2024
Full Text
View/download PDF

40. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

Author

Menzies, Alexander M., primary, Lo, Serigne N., additional, Saw, Robyn P.M., additional, Gonzalez, Maria, additional, Ch’ng, Sydney, additional, Nieweg, Omgo E., additional, Shannon, Kerwin F., additional, Ferguson, Peter M., additional, Lee, Jenny, additional, Emmett, Louise, additional, Kapoor, Rony, additional, Rawson, Robert V., additional, Stretch, Jonathan R., additional, Thompson, John F., additional, Spillane, Andrew J., additional, Rizos, Helen, additional, Scolyer, Richard A., additional, and Long, Georgina V., additional

Published
2024
Full Text
View/download PDF

41. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Author

Reijers, Irene L. M., Menzies, Alexander M., van Akkooi, Alexander C. J., Versluis, Judith M., van den Heuvel, Noëlle M. J., Saw, Robyn P. M., Pennington, Thomas E., Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Rozeman, Elisa A., Klop, Willem M. C., van Houdt, Winan J., Sikorska, Karolina, van der Hage, Jos A., Grünhagen, Dirk J., Wouters, Michel W., Witkamp, Arjen J., Zuur, Charlotte L., Lijnsvelt, Judith M., Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F., Ch’ng, Sydney, Colebatch, Andrew J., Spillane, Andrew J., Haanen, John B. A. G., Rawson, Robert V., van de Wiel, Bart A., van de Poll-Franse, Lonneke V., Scolyer, Richard A., Boekhout, Annelies H., Long, Georgina V., and Blank, Christian U.

Published
2022
Full Text
View/download PDF

42. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Author

van Akkooi, Alexander C. J., Hieken, Tina J., Burton, Elizabeth M., Ariyan, Charlotte, Ascierto, Paolo A., Asero, Salvatore V. M. A., Blank, Christian U., Block, Matthew S., Boland, Genevieve M., Caraco, Corrado, Chng, Sydney, Davidson, B. Scott, Duprat Neto, Joao Pedreira, Faries, Mark B., Gershenwald, Jeffrey E., Grunhagen, Dirk J., Gyorki, David E., Han, Dale, Hayes, Andrew J., van Houdt, Winan J., Karakousis, Giorgos C., Klop, Willem M. C., Long, Georgina V., Lowe, Michael C., Menzies, Alexander M., Olofsson Bagge, Roger, Pennington, Thomas E., Rutkowski, Piotr, Saw, Robyn P. M., Scolyer, Richard A., Shannon, Kerwin F., Sondak, Vernon K., Tawbi, Hussein, Testori, Alessandro A. E., Tetzlaff, Mike T., Thompson, John F., Zager, Jonathan S., Zuur, Charlotte L., Wargo, Jennifer A., Spillane, Andrew J., and Ross, Merrick I.

Published
2022
Full Text
View/download PDF

43. Anatomic position determines oncogenic specificity in melanoma

Author

Weiss, Joshua M., Hunter, Miranda V., Cruz, Nelly M., Baggiolini, Arianna, Tagore, Mohita, Ma, Yilun, Misale, Sandra, Marasco, Michelangelo, Simon-Vermot, Theresa, Campbell, Nathaniel R., Newell, Felicity, Wilmott, James S., Johansson, Peter A., Thompson, John F., Long, Georgina V., Pearson, John V., Mann, Graham J., Scolyer, Richard A., Waddell, Nicola, Montal, Emily D., Huang, Ting-Hsiang, Jonsson, Philip, Donoghue, Mark T. A., Harris, Christopher C., Taylor, Barry S., Xu, Tianhao, Chaligné, Ronan, Shliaha, Pavel V., Hendrickson, Ronald, Jungbluth, Achim A., Lezcano, Cecilia, Koche, Richard, Studer, Lorenz, Ariyan, Charlotte E., Solit, David B., Wolchok, Jedd D., Merghoub, Taha, Rosen, Neal, Hayward, Nicholas K., and White, Richard M.

Published
2022
Full Text
View/download PDF

45. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma

Author

Thompson, John F., Hyngstrom, John, Caracò, Corrado, Zager, Jonathan S., Jahkola, Tiina, Bowles, Tawnya L., Pennacchioli, Elisabetta, Hoekstra, Harald J., Moncrieff, Marc, Ingvar, Christian, van Akkooi, Alexander, Sabel, Michael S., Levine, Edward A., Henderson, Michael, Dummer, Reinhard, Rossi, Carlo Riccardo, Kane, 3rd, John M., Trocha, Steven, Wright, Frances, Byrd, David R., Matter, Maurice, MacKenzie-Ross, Alastair, Kelley, Mark C., Terheyden, Patrick, Huston, Tara L., Wayne, Jeffrey D., Neuman, Heather, Smithers, B. Mark, Desai, Darius, Gershenwald, Jeffrey E., Schneebaum, Shlomo, Gesierich, Anja, Jacobs, Lisa K., Lewis, James M., O’Donoghue, Cristina, Sardi, Armando, McKinnon, J. Greg, Slingluff, Craig L., Farma, Jeffrey M., Schultz, Erwin, Scheri, Randall P., Vidal-Sicart, Sergi, Testori, Alessandro A. E., Scolyer, Richard A., Elashoff, David E., Cochran, Alistair J., and Faries, Mark B.

Published
2023
Full Text
View/download PDF

46. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Author

Newell, Felicity, Kong, Yan, Wilmott, James S, Johansson, Peter A, Ferguson, Peter M, Cui, Chuanliang, Li, Zhongwu, Kazakoff, Stephen H, Burke, Hazel, Dodds, Tristan J, Patch, Ann-Marie, Nones, Katia, Tembe, Varsha, Shang, Ping, van der Weyden, Louise, Wong, Kim, Holmes, Oliver, Lo, Serigne, Leonard, Conrad, Wood, Scott, Xu, Qinying, Rawson, Robert V, Mukhopadhyay, Pamela, Dummer, Reinhard, Levesque, Mitchell P, Jönsson, Göran, Wang, Xuan, Yeh, Iwei, Wu, Hong, Joseph, Nancy, Bastian, Boris C, Long, Georgina V, Spillane, Andrew J, Shannon, Kerwin F, Thompson, John F, Saw, Robyn PM, Adams, David J, Si, Lu, Pearson, John V, Hayward, Nicholas K, Waddell, Nicola, Mann, Graham J, Guo, Jun, and Scolyer, Richard A

Subjects
Melanocytes, Humans, Melanoma, Telomerase, Signal Transduction, Point Mutation, Female, Male, Cyclin-Dependent Kinase 4, Proto-Oncogene Proteins c-mdm2, DNA Copy Number Variations, Biomarkers, Tumor, Whole Genome Sequencing, Biomarkers, Tumor
Abstract

Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the paucity of comprehensive mutation data on this rare tumor type. To better understand the genomic landscape of mucosal melanoma, here we describe whole genome sequencing analysis of 67 tumors and validation of driver gene mutations by exome sequencing of 45 tumors. Tumors have a low point mutation burden and high numbers of structural variants, including recurrent structural rearrangements targeting TERT, CDK4 and MDM2. Significantly mutated genes are NRAS, BRAF, NF1, KIT, SF3B1, TP53, SPRED1, ATRX, HLA-A and CHD8. SF3B1 mutations occur more commonly in female genital and anorectal melanomas and CTNNB1 mutations implicate a role for WNT signaling defects in the genesis of some mucosal melanomas. TERT aberrations and ATRX mutations are associated with alterations in telomere length. Mutation profiles of the majority of mucosal melanomas suggest potential susceptibility to CDK4/6 and/or MEK inhibitors.

Published
2019

47. LNK suppresses interferon signaling in melanoma.

Author

Ding, Ling-Wen, Sun, Qiao-Yang, Edwards, Jarem J, Fernández, Lucia Torres, Ran, Xue-Bin, Zhou, Si-Qin, Scolyer, Richard A, Wilmott, James S, Thompson, John F, Doan, Ngan, Said, Jonathan W, Venkatachalam, Nachiyappan, Xiao, Jin-Fen, Loh, Xin-Yi, Pein, Maren, Xu, Liang, Mullins, David W, Yang, Henry, Lin, De-Chen, and Koeffler, H Phillip

Subjects
Cell Line, Tumor, Animals, Mice, Inbred C57BL, Mice, Inbred NOD, Humans, Mice, Mice, SCID, Melanoma, Skin Neoplasms, Intracellular Signaling Peptides and Proteins, Proteins, Interferons, Xenograft Model Antitumor Assays, Apoptosis, STAT1 Transcription Factor, HEK293 Cells, Cell Cycle Checkpoints, Membrane Proteins, Cell Line, Tumor, Inbred C57BL, Inbred NOD, SCID
Abstract

LNK (SH2B3) is a key negative regulator of JAK-STAT signaling which has been extensively studied in malignant hematopoietic diseases. We found that LNK is significantly elevated in cutaneous melanoma; this elevation is correlated with hyperactive signaling of the RAS-RAF-MEK pathway. Elevated LNK enhances cell growth and survival in adverse conditions. Forced expression of LNK inhibits signaling by interferon-STAT1 and suppresses interferon (IFN) induced cell cycle arrest and cell apoptosis. In contrast, silencing LNK expression by either shRNA or CRISPR-Cas9 potentiates the killing effect of IFN. The IFN-LNK signaling is tightly regulated by a negative feedback mechanism; melanoma cells exposed to IFN upregulate expression of LNK to prevent overactivation of this signaling pathway. Our study reveals an unappreciated function of LNK in melanoma and highlights the critical role of the IFN-STAT1-LNK signaling axis in this potentially devastating disease. LNK may be further explored as a potential therapeutic target for melanoma immunotherapy.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results